John G Smart

US Patent:

6399569, Jun 4, 2002

Filed:

Jun 5, 1995

Appl. No.:

08/461113

Inventors:

Charles M. Cohen - Medway MA
Marc F. Charette - Needham MA
David C. Rueger - Hopkinton MA
Hermann Oppermann - Medway MA
Roy H. L. Pang - Etna NH
Engin Ozkaynak - Milford MA
John E. Smart - Weston MA

Assignee:

Curis, Inc. - Cambridge MA

International Classification:

A61K 3818

US Classification:

514 12, 530350

Abstract:

Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.

US Patent:

6949505, Sep 27, 2005

Filed:

Aug 18, 1994

Appl. No.:

08/292782

Inventors:

David C. Rueger - Hopkinton MA, US
Kuber T. Sampath - Medway MA, US
John E. Smart - Weston MA, US
Hermann Oppermann - Medway MA, US
Engin Ozkaynak - Milford MA, US
Charles M. Cohen - Weston MA, US
Dennis Higgins - Amherst NY, US

Assignee:

Curis, Inc. - Cambridge MA
The Research Foundation of State University of New York - Amherst NY

International Classification:

A01N037/18

US Classification:

514 2, 530300, 530350

Abstract:

Disclosed are methods and compositions for maintaining neural pathways in a mammal including: enhancing survival of neurons at risk of dying; inducing cellular repair of damaged neurons and neural pathways; stimulating neurons to maintain their differentiated phenotype; and promoting dendritic outgrowth, including maintaining dendritic arbors and regenerating dendritic architecture. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration. In another embodiment, the invention provides methods and compositions which include a morphogen or morphogen-stimulating agent, and a nerve trophic factor or nerve trophic factor-stimulating agent at concentrations effective for stimulating dendrite outgrowth. The morphogen and the nerve trophic factor can be admixed in combination.

US Patent:

7056882, Jun 6, 2006

Filed:

Sep 13, 2001

Appl. No.:

09/952318

Inventors:

Charles M. Cohen - Weston MA, US
Herrmann Oppermann - Medway MA, US
Engin Ozkaynak - Milford MA, US
David C. Rueger - Hopkinton MA, US
John E. Smart - Weston MA, US
Roy H. L. Pang - Etna NH, US

Assignee:

Curis, Inc. - Cambridge MA

International Classification:

A61K 38/18
A61K 38/16

US Classification:

514 2, 514 12, 424 851

Abstract:

The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.

US Patent:

7060680, Jun 13, 2006

Filed:

Jan 15, 2002

Appl. No.:

10/050050

Inventors:

Charles M. Cohen - Medway MA, US
Marc F. Charette - Needham MA, US
David C. Rueger - Hopkinton MA, US
Hermann Oppermann - Medway MA, US
Roy H. L. Pang - Etna NH, US
Engin Ozkaynak - Milford MA, US
John E. Smart - Weston MA, US

Assignee:

Curis, Inc. - Cambridge MA

International Classification:

A61K 38/18
C07K 14/51

US Classification:

514 12, 530350

Abstract:

Disclosed are methods and compositions for maintaining the integrity of the gastrointestinal tract luminal lining in a mammal, including (1) limiting epithelial cell proliferation, (2) inhibiting ulcerative lesion formation, (3) inhibiting inflammation normally associated with ulcerative diseases, and (4) stimulating the repair of ulcerative lesions and the regeneration of the luminal tissue. The methods and compositions include a therapeutically effective amount of a morphogen as defined herein.

US Patent:

20060025571, Feb 2, 2006

Filed:

Sep 13, 2005

Appl. No.:

11/226555

Inventors:

David Rueger - Hopkinton MA, US
Kuber Sampath - Holliston MA, US
John Smart - Weston MA, US
Hermann Oppermann - Medway MA, US
Engin Ozkaynak - Milford MA, US
Charles Cohen - Weston MA, US
Dennis Higgins - Amherst NY, US

Assignee:

Curis, Inc. - Cambridge MA

International Classification:

A61K 38/18
C07K 14/475

US Classification:

530350000, 514012000

Abstract:

Disclosed are methods and compositions for maintaining neural pathways in a mammal including: enhancing survival of neurons at risk of dying; inducing cellular repair of damaged neurons and neural pathways; stimulating neurons to maintain their differentiated phenotype; and promoting dendritic outgrowth, including maintaining dendritic arbors and regenerating dendritic architecture. In one embodiment, the invention provides means for stimulating CAM expression in neurons. The invention also provides means for evaluating the status of nerve tissue, including means for detecting and monitoring neuropathies in a mammal. The methods, devices and compositions include a morphogen or morphogen-stimulating agent provided to the mammal in a therapeutically effective concentration. In another embodiment, the invention provides methods and compositions which include a morphogen or morphogen-stimulating agent, and a nerve trophic factor or nerve trophic factor-stimulating agent at concentrations effective for stimulating dendrite outgrowth. The morphogen and the nerve trophic factor can be admixed in combination.

US Patent:

59941316, Nov 30, 1999

Filed:

Aug 15, 1997

Appl. No.:

8/912088

Inventors:

John E. Smart - Weston MA
Hermann Oppermann - Medway MA
Engin Ozkaynak - Milford MA
David C. Rueger - Hopkinton MA
Roy H. L. Pang - Etna NH
Charles M. Cohen - Medway MA

Assignee:

Creative BioMolecules, Inc. - Hopkinton MA

International Classification:

C12N 506
C12N 508

US Classification:

435354

Abstract:

Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture known to produce the morphogen, incubating a candidate compound with the culture for a time sufficient to allow the compound to affect the production of the morphogenic protein, and then assaying the culture again to detect a change in the level of morphogenic protein production.

US Patent:

63333120, Dec 25, 2001

Filed:

Oct 13, 1998

Appl. No.:

9/170936

Inventors:

Charles M. Cohen - Weston MA
Herrmann Oppermann - Medway MA
Engin Ozkaynak - Milford MA
David C. Rueger - Hopkinton MA
John E. Smart - Weston MA
Roy H. L. Pang - Etna NH

Assignee:

Curis, Inc.

International Classification:

C07K 14435
C07K 14475

US Classification:

514 12

Abstract:

The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.

US Patent:

56502761, Jul 22, 1997

Filed:

Jul 20, 1994

Appl. No.:

8/278729

Inventors:

John E. Smart - Weston MA
Hermann Oppermann - Medway MA
Engin Ozkaynak - Milford MA
David C. Rueger - Hopkinton MA
Roy H.L. Pang - Etna NH
Charles M. Cohen - Medway MA

Assignee:

Creative BioMolecules, Inc. - Hopkinton MA

International Classification:

C12Q 168
C12Q 102

US Classification:

435 6

Abstract:

Disclosed is a method of screening candidate compounds for the ability to modulate the level of morphogenic protein in mammalian system. The method includes determining a parameter indicative of the level of production of a morphogenic in a cell culture known to produce the morphogen, incubating a candidate compound with the culture for a time sufficient to allow the compound to affect the production of the morphogenic protein, and then assaying the culture again to detect a change in the level of morphogenic protein production.